mfn-cus-regulatory-press-releases

Nanologica Changes Dates for Financial Reports

19 January, 2022

Nanologica's Year-end report for 2021 will be published on Tuesday February 8, instead of January 31 as previously announced, and the company's Annual Report for 2021 will be published on Wednesday March 9, instead of April 8 as previously announced. Dates for upcoming financial reports: Year-end report 2021 8 February, 2022 Annual Report 2021 9 March,

Nanologica Signs Credit Line with Main Owner

19 January, 2022

Nanologica AB has signed a credit line of up to MSEK 50 with the company's main owner Flerie Invest AB. The aim is to cover the company's temporary financial needs pending expected cash flows from the preparative chromatography business, to meet the requirement of going concern for the next twelve months. This loan financing is a flexible way to meet the company's short-term capital needs pending expected cash flows from the preparative chromatography business. The

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.